Brief: Galectin Reports Positive Outcome Of First Data And Safety Monitoring Board For Study Of Belapectin
14/04/2022 12:58
April 14 (Reuters) - Galectin Therapeutics Inc GALT.O :
* GALECTIN THERAPEUTICS REPORTS THE POSITIVE OUTCOME OF THE
FIRST
DATA AND SAFETY MONITORING BOARD FOR NAVIGATE, ITS SEAMLESS,
ADAPTIVE PHASE 2B/3 STUDY OF BELAPECTIN IN PATIENTS WITH LIVER
CIRRHOSIS CAUSED BY NON-ALCOHOLIC STEATOHEPATITIS
Source text: (https://bit.ly/37myYiZ)
Further company coverage: GALT.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Galectin Therapeutics
See all newsGalectin Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
Brief: Galectin Therapeutics Reports June 30, 2026 Financial Results
Galectin Therapeutics Q2 loss widens
Galectin Therapeutics Inc expected to post a loss of 9 cents a share - Earnings Preview
Galectin Therapeutics rises as FDA clears path for late-stage liver drug study